Consensus Recommendations for Clinical Pharmacist Integration into the Acute Stroke Care Team

Read the article record on PubMed

What the panel recommends

Using GRADE—the Grading of Recommendations, Assessment, Development, and Evaluation approach—the panel made two conditional recommendations in favor of pharmacist involvement. One addresses acute ischemic stroke; the other addresses hemorrhagic stroke, with supporting evidence focused on oral-anticoagulant reversal. Recommendation strength and evidence certainty answer different questions: whether to favor an action, and how confident to be in its estimated effects.¹

Two different treatment clocks

For ischemic stroke, ten observational studies, all at high risk of bias, informed the evidence assessment. Pharmacist involvement was associated with a pooled 15.1-minute shorter door-to-needle time (95% confidence interval, 11.2 to 18.9 minutes shorter). The evidence evaluated alteplase; the same effect size has not been established for tenecteplase.¹

For anticoagulation reversal, six observational studies, also at high risk of bias, informed the assessment. The pooled medication-order-to-administration interval was 18.7 minutes shorter with pharmacist involvement (95% confidence interval, 14.0 to 23.5 minutes shorter). This interval starts at the order, not emergency-department arrival. Studies included intracranial and extracranial bleeding, and intracranial-only results could not be separately pooled.¹

What a pharmacist can put into practice

Map who verifies the medication history and last anticoagulant dose, checks eligibility and contraindications with the stroke team, verifies the selected drug and dose, and coordinates retrieval, preparation, and administration. Use current institutional protocols for treatment and blood-pressure decisions. Training, simulation, and clear handoffs make these responsibilities concrete.¹

When bedside coverage is limited

The authors discuss peak-hour coverage, cross-coverage, on-call consultation, and rapid chart review when continuous bedside staffing is not feasible. Telepharmacy is a possible way to extend access, but its stroke-specific benefit remains an evidence gap. A local plan should identify who can respond, how the team contacts that person, and which responsibilities remain with the bedside team.¹

A responsible service proposal

Application: propose a defined pharmacist role and measure door-to-needle time separately from reversal order-to-administration time. Record coverage gaps and medication-safety problems alongside timing. Observational studies can be affected by staffing and concurrent workflow changes, so the pooled time savings are not a guaranteed local effect. Improved long-term function, mortality, and stroke-specific cost savings remain unproven by this evidence base.¹

Sources

1. Gilbert BW, Brown CS, Acquisto NM, et al. Consensus Recommendations for Clinical Pharmacist Integration into the Acute Stroke Care Team: Endorsed by the American College of Clinical Pharmacy, Neurocritical Care Society, Society for Academic Emergency Medicine, and Society of Critical Care Medicine, and affirmed by the American Academy of Neurology. J Am Coll Clin Pharm. 2026;9(7):e70246. doi:10.1002/jac5.70246. PubMed.

Related evidence

The consensus draws on these reviews. Their underlying studies overlap with its evidence base and should not be counted as independent replication.

• PhAST-1: pharmacist involvement and fibrinolytic door-to-needle time.
• Pharmacist participation and time to oral-anticoagulant reversal.

ACPE UAN: 0683-0000-26-036-H01-P